Search Results

You are looking at 151 - 160 of 183 items for :

  • "tamoxifen" x
  • Refine by Access: All x
Clear All
Full access

Mod C. Chandhanayingyong, Nicholas M. Bernthal, Piti Ungarreevittaya, Scott D. Nelson, Sant P. Chawla, and Arun S. Singh

paclitaxel. She received 4 cycles of doxorubicin at 60 mg/m 2 . She was not given adjuvant tamoxifen because data supporting its adjuvant use was not mature at that time. In the setting of bilateral breast cancer in a young woman with maternal Ashkenazi

Full access

Siu-Fun Wong, Mark Bounthavong, Cham P. Nguyen, and Timothy Chen

. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer . Lancet 2005 ; 365 : 60 – 62 . 21. Chlebowski RT Geller ML . Adherence to endocrine therapy for

Full access

Heidi Klepin, Supriya Mohile, and Arti Hurria

effect of comorbidity on 3-year survival of women with primary breast cancer . Ann Intern Med 1994 ; 120 : 104 – 110 . 29 Hughes KS Schnaper LA Berry D . Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or

Full access

Tilmann Bochtler, Volker Endris, Anna Reiling, Jonas Leichsenring, Michal R. Schweiger, Sebastian Klein, Fabian Stögbauer, Benjamin Goeppert, Peter Schirmacher, Alwin Krämer, and Albrecht Stenzinger

hormone receptor–positive (estrogen receptor [ER], 12/12; progesterone receptor [PR], 8/12; HER2/neu, 1+) ductal adenocarcinoma of luminal type B, which was treated with surgical resection and subsequent adjuvant tamoxifen, which is still ongoing at time

Full access

Arti Hurria, Ilene S. Browner, Harvey Jay Cohen, Crystal S. Denlinger, Mollie deShazo, Martine Extermann, Apar Kishor P. Ganti, Jimmie C. Holland, Holly M. Holmes, Mohana B. Karlekar, Nancy L. Keating, June McKoy, Bruno C. Medeiros, Ewa Mrozek, Tracey O’Connor, Stephen H. Petersdorf, Hope S. Rugo, Rebecca A. Silliman, William P. Tew, Louise C. Walter, Alva B. Weir III, and Tanya Wildes

receptor–positive breast cancer to receive lumpectomy and tamoxifen with whole-breast RT or lumpectomy and tamoxifen for 5 years, no differences were seen in overall survival or breast cancer–specific survival. 249 , 250 However, locoregional recurrence

Full access

Jimmie C. Holland, Barbara Andersen, William S. Breitbart, Bruce Compas, Moreen M. Dudley, Stewart Fleishman, Caryl D. Fulcher, Donna B. Greenberg, Carl B. Greiner, Rev. George F. Handzo, Laura Hoofring, Paul B. Jacobsen, Sara J. Knight, Kate Learson, Michael H. Levy, Matthew J. Loscalzo, Sharon Manne, Randi McAllister-Black, Michelle B. Riba, Kristin Roper, Alan D. Valentine, Lynne I. Wagner, and Michael A. Zevon

possible mechanisms. 21 Nonadherence to treatment occurs, especially with oral medications. In women with primary breast cancer, Partridge et al. 22 observed that the overall adherence to tamoxifen decreased to 50% in the fourth year of therapy, and that

Full access

Jimmie C. Holland, Barbara Andersen, William S. Breitbart, Luke O. Buchmann, Bruce Compas, Teresa L. Deshields, Moreen M. Dudley, Stewart Fleishman, Caryl D. Fulcher, Donna B. Greenberg, Carl B. Greiner, Rev. George F. Handzo, Laura Hoofring, Charles Hoover, Paul B. Jacobsen, Elizabeth Kvale, Michael H. Levy, Matthew J. Loscalzo, Randi McAllister-Black, Karen Y. Mechanic, Oxana Palesh, Janice P. Pazar, Michelle B. Riba, Kristin Roper, Alan D. Valentine, Lynne I. Wagner, Michael A. Zevon, Nicole R. McMillian, and Deborah A. Freedman-Cass

to tamoxifen decreased to 50% in the fourth year of therapy and nearly one-fourth of patients may be at risk of inadequate clinical response because of poor adherence. In a meta-analysis, DiMatteo et al 17 found that non-compliance was 3 times

Full access

Benjamin L. Franc, Timothy P. Copeland, Robert Thombley, Miran Park, Ben Marafino, Mitzi L. Dean, W. John Boscardin, Hope S. Rugo, David Seidenwurm, Bhupinder Sharma, Stephen R. Johnston, and R. Adams Dudley

not make sense, particularly when the patient may require symptom-driven imaging studies for 20 years after completion of 5 years of tamoxifen. Depending on treatment and geographic location, our study found that 18% to 46% of patients received high

Full access

Mathias Kvist Mejdahl, Birgitte Goldschmidt Mertz, Pernille Envold Bidstrup, and Kenneth Geving Andersen

treatment consisted of tamoxifen or aromatase inhibitor according to hormonal receptor status and menopausal status. Statistical Analyses Statistical analyses were performed with SPSS Statistics for Windows, Version 19.0 (IBM Corp, Armonk, NY

Full access

Hanna K. Sanoff, YunKyung Chang, Joseph M. Stavas, Til Stürmer, and Jennifer Lund

phase III trial comparing tamoxifen alone or with transarterial lipiodol chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Federation Francophone de Cancerologie Digestive 9402) . Eur J Cancer 2008 ; 44 : 528 – 538